IVA is a high-risk, high-reward biotech stock hinging on lanifibranor’s Phase 3 NATiV3 MASH readout by Q4 2026. Click here to ...

Researchers at Helmholtz Munich have engineered a hybrid obesity drug that uses GLP-1 receptors to smuggle a second metabolic ...

What was discovered: Researchers created a quintuple agonist that uses GLP-1 receptors to deliver a PPAR drug directly into target cells, reversing obesity and diabetes in mice. Why it matters: The ...

Researchers have created a next-generation obesity drug that works like a “Trojan horse,” using GLP-1/GIP signals to slip a ...

Cinnamon, Bitter Melon, Resveratrol, Licorice Root, Turmeric, and Coriander in the Blood Sugar Trap Liquid Tincture Formula ...

A new preclinical study in Nature reports a single-molecule therapy that combines GLP-1 and GIP receptor activation with triple PPAR agonism, delivering greater weight loss and metabolic benefits in ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Ascendant Health Sciences, Cue, Esperion, Eton, J&J, Noxopharm.

This innovative compound is known as a 'quintuple agonist' because it combines the power of GLP-1 and glucose-dependent ...

The scientists observed metabolic changes in both male and female offspring of nicotine-exposed fathers. According to them, the results highlight the importance of paternal health before conception, ...

The arterial pole of the heart is a hotspot for life-threatening forms of congenital heart defects (CHDs). Development of this cardiac region occurs by addition of Second Heart Field (SHF) progenitor ...

WASHINGTON -- Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...